Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy for Alzheimer's disease.

Richard C Dodel1, Harald Hampel, Yansheng Du

  • 1Department of Neurology, Friedrich-Wilhelms-University Bonn, Germany. richard.dodel@ukb.uni-bonn.de <richard.dodel@ukb.uni-bonn.de>

The Lancet. Neurology
|July 10, 2003
PubMed
Summary

Active immunization targeting amyloid-beta in Alzheimer's disease (AD) models shows promise by activating microglia to reduce plaque pathology. However, clinical trials were halted due to adverse events, highlighting the need for safer immunotherapy strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GWAS meta-analysis of cerebrospinal fluid Alzheimer's biomarkers reveals loci regulating lipids, brain volume and autophagy.

Nature communications·2026
Same author

Revising the ABIDE MCI to dementia prediction model for automated cerebrospinal fluid assays.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Advancing Early Detection of Alzheimer Disease in the Primary Care Setting in the United States.

Neurology. Clinical practice·2025
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Alzheimer's disease (AD) is characterized by amyloid-beta (Abeta) plaques.
  • Murine models show Abeta immunotherapy can reduce plaque pathology via microglial activation.
  • Antibodies against Abeta are detectable in serum and cerebrospinal fluid (CSF).

Purpose of the Study:

  • To review immunotherapy strategies for Alzheimer's disease.
  • To explore antibody-mediated clearance of Abeta.
  • To discuss the role of neuroinflammation in AD.

Main Methods:

  • Review of preclinical studies in murine AD models.
  • Analysis of clinical trial data for AN1792 active immunization.
  • Examination of antibody detection in serum and CSF.

Related Experiment Videos

Main Results:

  • Active and passive immunization reduced Abeta plaque pathology in mice.
  • Clinical trial AN1792 suspended due to severe adverse events linked to proinflammatory cascade activation.
  • The precise role and specificity of anti-Abeta antibodies in AD progression remain undetermined.

Conclusions:

  • Immunotherapy targeting Abeta offers a potential strategy to test the amyloid hypothesis in AD.
  • Neuroinflammation may play a complex role in AD pathogenesis.
  • Further research is needed to develop safe and effective Abeta-targeted immunotherapies for Alzheimer's disease.